The relationship between cannabis and mental health is complex and bidirectional. Many people use cannabis to self-medicate anxiety and depression, but chronic use can worsen both conditions through endocannabinoid system disruption, amygdala sensitisation, and dopamine dysregulation. High-potency THC use is associated with a significantly increased risk of psychotic disorders, particularly in adolescents and individuals with genetic vulnerability. A Lancet Psychiatry study found that daily use of high-potency cannabis was associated with approximately five times greater odds of first-episode psychosis compared to non-use. Understanding the neuroscience behind these relationships is essential for anyone using cannabis to manage mental health symptoms.
Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician, Phuket Island Rehab
“The most common pattern we see at Phuket Island Rehab is someone who began using cannabis for anxiety and is now significantly more anxious than before they started,” says Dr. Ponlawat Pitsuwan. “THC provides short-term anxiolytic relief through CB1 receptor activation in the amygdala, but chronic exposure sensitises the anxiety circuitry so that baseline anxiety increases. The person then uses more cannabis to manage the elevated anxiety, creating a cycle that progressively worsens the condition it was meant to treat.”
Cannabis and Anxiety: The Paradox
THC has a biphasic effect on anxiety. At low doses, THC activates CB1 receptors in the amygdala and prefrontal cortex, reducing anxiety through modulation of GABA and glutamate neurotransmission. This is the anxiolytic effect that draws many users to cannabis. At higher doses, THC produces anxiogenic effects: paranoia, racing thoughts, and heightened threat perception. This dose-dependent relationship means that the same compound can reduce anxiety at one dose and dramatically worsen it at another.
With chronic use, the endocannabinoid system adapts through CB1 receptor downregulation. The brain’s baseline capacity for stress regulation, which depends on functioning endocannabinoid tone, is diminished. This means that between cannabis sessions, the user experiences elevated anxiety compared to their pre-cannabis baseline. The cannabis is no longer reducing anxiety below normal; it is temporarily restoring a deficit that cannabis itself created. This is the hallmark of dependence masquerading as self-medication.
Cannabis and Depression
The relationship between cannabis and depression is similarly complex. Cross-sectional studies consistently show higher rates of depression among regular cannabis users, and longitudinal studies suggest that heavy cannabis use in adolescence is associated with increased risk of depression in young adulthood, with a modest but significant dose-response relationship. The proposed mechanisms include chronic dopamine dysregulation (cannabis suppresses dopamine synthesis capacity over time, which impairs reward sensitivity and motivation), disruption of serotonergic signalling, and the amotivational effects of chronic CB1 receptor activation.
The amotivational syndrome described in clinical literature, characterised by reduced drive, decreased goal-directed behaviour, apathy, and emotional flattening, overlaps substantially with the symptoms of major depression. Whether this represents a direct pharmacological effect of chronic THC exposure or a consequence of the lifestyle changes associated with heavy cannabis use (social withdrawal, reduced physical activity, disrupted sleep) is debated, but the clinical presentation is similar enough that distinguishing cannabis-induced amotivation from primary depression requires a period of sustained abstinence.
Cannabis and Psychosis Risk
The association between cannabis use and psychotic disorders is the most robustly established mental health risk of cannabis. The evidence comes from multiple large prospective cohort studies, dose-response analyses, and neurobiological plausibility. THC stimulates dopamine release in the mesolimbic pathway, and the dopamine hypothesis of psychosis proposes that excessive mesolimbic dopamine activity underlies positive psychotic symptoms (hallucinations, delusions, disorganised thinking).
The Di Forti et al. study published in The Lancet Psychiatry in 2019 analysed first-episode psychosis across 11 sites in Europe and Brazil. The findings showed that daily use of high-potency cannabis (greater than 10% THC) was associated with approximately five-fold increased odds of psychotic disorder compared to never-use. In Amsterdam and London, where high-potency cannabis dominates the market, the population-attributable fraction suggested that 30 to 50% of new psychosis cases could be prevented if high-potency cannabis were not available.
Warning: Cannabis-induced psychosis can be the first presentation of schizophrenia in genetically vulnerable individuals. Individuals with a family history of schizophrenia or psychotic disorders face substantially elevated risk from cannabis use. Adolescent use during the critical neurodevelopmental window is particularly concerning, as the brain’s dopamine system is still maturing and may be permanently altered by heavy THC exposure during this period.
Mental Health Risk by Cannabis Use Pattern
| Use Pattern | Anxiety Impact | Depression Impact | Psychosis Risk |
|---|---|---|---|
| Occasional low-potency use (monthly or less) | Minimal; may provide transient relief | No significant association | Minimal increase |
| Weekly moderate-potency use | Possible emerging tolerance; rebound anxiety between sessions | Modest association in longitudinal studies | Modest increase (approximately 2x) |
| Daily high-potency use | Likely worsened baseline anxiety; dependence-driven use | Significantly associated with depression risk | Approximately 5x increased odds (Di Forti et al.) |
| Daily concentrate use (60 to 90% THC) | High probability of worsened anxiety and panic attacks | Strong association; amotivation common | Highest risk category (dose-response) |
The Self-Medication Trap
Many people begin using cannabis specifically to manage anxiety, depression, PTSD symptoms, or insomnia. In the short term, this self-medication can feel effective: THC reduces acute anxiety, elevates mood, and promotes sleep onset. The problem is that these effects depend on a functioning endocannabinoid system, and chronic THC exposure degrades exactly that system. Over weeks and months, tolerance develops, the therapeutic window narrows, and the underlying condition worsens during the increasingly frequent periods between use.
The self-medication model also masks the underlying condition from clinical detection. A person using cannabis daily for anxiety may never seek formal evaluation or receive evidence-based treatment (CBT, SSRIs, or other established interventions) because the cannabis provides enough moment-to-moment relief to avoid the discomfort that would otherwise drive help-seeking. Meanwhile, the untreated anxiety condition may be progressing, and the cannabis dependence adds a second clinical problem that complicates eventual treatment.
Clinical insight: At Phuket Island Rehab, patients with co-occurring cannabis use disorder and anxiety or depression undergo a supervised cannabis-free period of at least 4 to 6 weeks before definitive psychiatric diagnosis. This is because many symptoms attributed to a primary psychiatric condition resolve substantially once the endocannabinoid system normalises. If significant symptoms persist after 4 to 6 weeks of abstinence, a primary psychiatric diagnosis is more reliably established and evidence-based treatment can be initiated.
When Substance Use Has Become More Than Occasional
If you are using cannabis to manage anxiety, depression, or other mental health symptoms, and you have noticed that you need more cannabis for the same relief, that your symptoms are worse between sessions than they were before you started using, or that you cannot reduce your use despite wanting to, these are signs that self-medication has transitioned to dependence. The cannabis is no longer treating your mental health condition; it is maintaining a cycle that worsens it while preventing you from accessing treatments that would actually help.
Evidence-based treatments for anxiety and depression, including cognitive behavioural therapy, SSRI and SNRI medications, and structured therapeutic programmes, have strong efficacy data and do not produce the dependence and tolerance problems that cannabis self-medication creates. Residential treatment at Phuket Island Rehab addresses both the cannabis dependence and the co-occurring mental health condition in an integrated framework, allowing patients to achieve clarity about their baseline mental health once cannabis is removed from the equation.
Summary
Cannabis has a complex relationship with mental health that is often misunderstood. While THC provides short-term anxiolytic and mood-elevating effects, chronic use disrupts the endocannabinoid system in ways that worsen anxiety, contribute to depression, and significantly increase the risk of psychotic disorders. The self-medication model traps users in escalating dependence while preventing access to evidence-based psychiatric treatment. High-potency products and adolescent use carry the greatest risks. Understanding these neurobiological mechanisms empowers informed decisions about cannabis use and mental health management.
“The most important clinical question for any patient using cannabis for mental health symptoms is: is the cannabis treating the condition, or is it now part of the condition?” says Dr. Ponlawat Pitsuwan. “In our clinical experience, when chronic cannabis users undergo a supervised abstinence period, the majority find that their anxiety and mood symptoms improve substantially, often to their considerable surprise. The brain’s endocannabinoid system recovers, baseline emotional regulation normalises, and the patient discovers that the cannabis was maintaining the problem rather than solving it.”
Frequently Asked Questions
Can cannabis cause permanent mental health damage?
For most users, the mental health effects of cannabis are reversible upon sustained cessation. However, in individuals with genetic vulnerability to psychotic disorders, heavy cannabis use during adolescence may trigger the onset of schizophrenia or other psychotic conditions that would not have developed, or would have developed later and less severely, without cannabis exposure. Once a psychotic disorder is established, it requires ongoing psychiatric management regardless of whether cannabis use continues.
Does CBD help with anxiety without the THC risks?
CBD has shown anxiolytic properties in some clinical studies, but the evidence is preliminary and the optimal dosing is not established. CBD does not activate CB1 receptors and does not produce the dependence, tolerance, or psychosis risk associated with THC. However, many products marketed as CBD contain variable and sometimes significant amounts of THC. For anxiety management, evidence-based treatments (CBT, SSRIs) have far more robust clinical evidence than CBD.
How do I know if cannabis is making my anxiety worse?
Key indicators include needing cannabis just to feel “normal” rather than relaxed, experiencing worse anxiety between sessions than you did before you started using, escalating your dose or potency over time, having panic attacks during or after use (particularly at higher doses), and feeling that you cannot cope without cannabis. If your baseline anxiety, meaning your anxiety level when not using, is higher now than it was before you began regular cannabis use, the cannabis is likely contributing to the problem.
Is cannabis safer than antidepressants for depression?
No. SSRI and SNRI antidepressants have extensive clinical trial evidence demonstrating efficacy for major depression, do not produce tolerance requiring dose escalation, do not disrupt sleep architecture as cannabis does, and are not associated with psychosis risk. Cannabis has no clinical trial evidence supporting its efficacy for major depression and carries risks of dependence, worsened anxiety, amotivation, and psychosis. While antidepressants have their own side effects and considerations, the evidence base for their effectiveness in depression is incomparably stronger than for cannabis.
Does the type of cannabis matter for mental health effects?
Yes. Higher THC concentrations are associated with greater mental health risks, particularly psychosis risk. The THC:CBD ratio also matters; CBD may partially counteract some of THC’s adverse mental health effects, including anxiety and psychotic symptoms. Strains or products with higher CBD relative to THC may carry lower risk, though this does not eliminate the risks of chronic use, tolerance, and dependence. Concentrates (dabs, wax, shatter) with 60 to 90% THC represent the highest-risk products for mental health effects.
At what age is cannabis use most risky for mental health?
Adolescence (ages 12 to 17) is the highest-risk period. The brain is undergoing critical neurodevelopmental processes including prefrontal cortex maturation, dopamine system calibration, and endocannabinoid-guided synaptic pruning. Chronic THC exposure during this window disrupts these processes and is associated with the greatest increases in psychosis risk, depression risk, and cognitive impairment. The risk decreases with age of first use, though heavy use at any age carries mental health risks.
Sources
Di Forti M, et al. “The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe.” Lancet Psychiatry. 2019;6(5):427-436.
National Academies of Sciences, Engineering, and Medicine. “The Health Effects of Cannabis and Cannabinoids.” National Academies Press. 2017.
National Institute on Drug Abuse (NIDA). “Marijuana DrugFacts.” National Institutes of Health. drugabuse.gov
Cannabis · THC · CBD · CB1 receptor · Endocannabinoid system · Dopamine · Mesolimbic pathway · Amygdala · Psychosis · Schizophrenia · COMT gene · Di Forti study · Self-medication · Cannabis use disorder · DSM-5 · SSRIs · CBT · Phuket Island Rehab